Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Development of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cells

Figure 4

C-6 does not induce caspase or PARP cleavage. (A) MCF-10A, MCF-7, T47D, MDA-MB-231, hTERT-HMEC, PE1007070, PE1008032 and PE904557a cells were treated with DMSO (48 hours), 30 μM C-6 (48 hours), 1 μM staurosporine (24 hours) or 1 μg/mL TRAIL and 5 μM doxorubicin (24 hours) and the resulting whole cell lysates were analyzed by Western blot for cleaved caspase 3, caspase 8, cleaved caspase 9 and PARP. (B) MCF-10A, MCF-7, T47D, MDA-MB-231, PE1007070, PE1008032, PE904557a and PE110025 cells were treated with DMSO (48 hours), 30 μM C-6 (24 and 48 hours) or 1 μM staurosporine (24 hours) and the relative amount of caspase activity was measured using a luciferase-based Caspase-Glo assay and normalized to cell viability using a luciferase-based ATP assay. DMSO, dimethyl sulfoxide; HMEC, human mammary epithelial cells; hTERT, human telomerase; PE, pleural effusion; TRAIL, tumor necrosis factor related apoptosis inducing ligand.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us